Effect of green tea catechins on the pharmacokinetics of digoxin in humans

Tae-Eun Kim1
Kwang-Hee Shin2
Jeong-Eun Park2
Min-Gul Kim3
Yeo-Min Yun4
Dong-Hee Choi5
Kyoung Ja Kwon5
Jongmin Lee5

1Department of Clinical Pharmacology, Konkuk University Medical Center, Seoul, Republic of Korea; 2Department of Pharmacotherapy & Translational Research, College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Republic of Korea; 3Department of Pharmacology, Chonbuk National University Medical School, Jeonju, Jeonbuk, Republic of Korea; 4Department of Laboratory Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea; 5Department of Medical Science, Konkuk University School of Medicine, Seoul, Republic of Korea; 6Department of Rehabilitation Medicine, Konkuk University School of Medicine, Seoul, Republic of Korea

Correspondence: Jongmin Lee
Department of Rehabilitation Medicine, Konkuk University School of Medicine, 1 Hwayang-dong, Gwangjin-gu, Seoul 143-701, Republic of Korea
Tel +82 2 2030 5345
Email leej@kuh.ac.kr

Background: Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1. This study aimed to investigate the effect of green tea on the pharmacokinetics of digoxin, a typical probe drug of p-gp.

Methods: Sixteen healthy volunteers participated in this study. At Day 1, 0.5 mg of digoxin was administered via oral route. After a 14-day washout period, 630 mg of green tea catechins (GTC) was administered via oral route, followed by 0.5 mg of digoxin 1 hour later. From Day 16 through Day 28, 630 mg of GTC was administered alone. At Day 29, 630 mg of GTC and 0.5 mg of digoxin were administered in the same way as Day 15. Blood samples for the pharmacokinetic assessments of digoxin were collected up to 8 hours after each dose. Pharmacokinetic parameters were estimated by noncompartmental analysis. Area under the curve (AUC) and peak plasma concentration (Cmax) were compared using mixed effect model between digoxin alone and digoxin with GTC. ABCB1 was genotyped to determine whether its polymorphism affects digoxin–GTC interaction.

Results: Fifteen subjects completed the study. Compared to digoxin alone, the concomitant administration of digoxin and GTC significantly reduced the systemic exposure of digoxin: geometric mean ratios (GMR) and 90% confidence intervals (CI) of area under the concentration–time curve from time 0 to the last measurable time (AUC0last) and Cmax were 0.69 (0.62–0.75) and 0.72 (0.61–0.85), respectively. The concomitant administration of digoxin and GTC following pretreatment of GTC (Day 29) similarly reduced the AUC0last (GMR [90% CI]: 0.67 [0.61–0.74]) and Cmax (GMR [90% CI]: 0.74 [0.63–0.87]). In the comparison of the percentage changes from Day 1 (digoxin single administration) of AUC0last between genotypes, C1236T variant type showed a significant difference to wild-type on Day 15 (concomitant administration of digoxin and GTC) (P<0.005).

Conclusion: This study demonstrates that the coadministration of GTC reduces the systemic exposure of digoxin regardless of pretreatment of GTC.

Keywords: digoxin, green tea, catechin, p-glycoprotein, pharmacokinetics, drug interaction

Introduction

Green tea is one of the most popular beverages in Asia. Green tea is made up of catechins, which account for 30%–42% of the dried green tea leaves.1 Catechins in green tea include (+)-catechin (C), (+)-epicatechin (EC), (+)-epigallocatechin (EGC), (+)-epicatechin gallate (ECG), and (+)-epigallocatechin gallate (EGCG), of which EGCG is the most abundant one accounting for about half of the total catechin amount.2

Recently, green tea and its products have attracted significant attention worldwide, as they have been associated with various health benefits such as weight loss and prevention of cardiovascular disease or cancer.2,3–5 As green tea consumption increases, chances of significant interaction between drugs and green tea ingredients also may increase. Importantly, the concurrent use of a drug and green tea can alter the concentration of the drug, as the green tea catechins (GTC) can potentially interact...
with drug-metabolizing enzymes or transporters. Although no significant changes in cytochrome P450 by green tea or GTC have been observed, multiple studies have reported alterations in transporter activity by green tea or GTC. Roth et al. reported an in vitro study that GTC inhibited the uptake transporters organic anion transporting polypeptide (OATP)1A2, OATP1B1, and OATP2B1. Knop et al. also demonstrated the inhibition of various transporters by EGCG via an in vitro study. Misaka et al. reported in a clinical study that green tea ingestion greatly reduces the systemic exposure of nadolol by inhibiting OATP1A2-mediated uptake.

In contrast to the OATP transporters that exhibit significant interactions with GTC, p-glycoprotein (p-gp) has not been reported to interact with GTC in a study involving human subjects. P-gp is the well-characterized efflux transporter which is located in various organs such as the intestine, kidney, and liver to efflux drugs out of cells. We used digoxin to evaluate the effect of GTC on P-gp in vivo. Digoxin is used in patients with atrial fibrillation or congestive heart failure. It is one of the substrates of p-gp, and therefore its absorption and excretion are affected by p-gp. The US Food and Drug Administration recommended digoxin as one of the most suitable substrates for p-gp studies.

To investigate the effect of green tea on the pharmacokinetics of digoxin, we conducted an open-label, 3-treatment, fixed-sequence study (Figure 1) in Konkuk University Medical Center. The Institutional Review Boards of Konkuk University Medical Center (IRB No KUH1280094) approved the study protocol, and written informed consent was obtained from all subjects before study enrollment. All procedures were performed in accordance with the recommendations of the Declaration of Helsinki and Good Clinical Practices.

At Day 1, all the subjects were orally administered a 0.5 mg digoxin tablet. After a 14-day washout period, they were administered 630 mg of green tea extract followed by 0.5 mg digoxin 1 hour later. From Day 16 through 28, subjects only received 630 mg of GTC. At Day 29, the subjects were administered a 630 mg capsule of green tea extract followed by 0.5 mg digoxin 1 hour later, just like Day 15. Green tea extract was administered as a commercially available capsule Greentea catechin™ (Atlantic Essential Products, Inc., Hauppauge, NY, USA) containing 300 mg catechins. From the screening to the completion of the study, foods containing green tea constituents or grapefruit juice were not allowed. Concomitant medications were allowed only if it was not reported to induce or inhibit p-gp.

Pharmacokinetic analysis
For the analysis of digoxin pharmacokinetics, blood samples (8 mL) were taken predose and 1, 1.5, 2, 4, 6, and 8 hours after the administration of digoxin. Plasma was obtained by centrifugation at 3,000 rpm for 10 minutes and transferred.
into 3 polypropylene tubes. Plasma samples obtained after receiving digoxin were additionally transferred into 2 polypropylene tubes containing ascorbate-EDTA solution (20% ascorbic acid and 0.1% EDTA in 0.4 M NaH2PO4 buffer, pH 3.6) for the analysis of catechins. Plasma samples were stored at −80°C until analysis.

The peak plasma concentration (C_{max}) and time to C_{max} (ie, T_{max}) were directly obtained from the observed values. The area under the concentration–time curve (AUC) from time 0 to the last measurable time (AUC_{last}) was calculated using the trapezoidal rule. The elimination rate constant (λz) and AUC_{inf} were not determined due to the limitation of sampling time. Noncompartmental analyses were performed using Phoenix WinNonlin® (Certara, Princeton, NJ, USA).

**Bioanalysis of digoxin and catechins**

Plasma concentrations of digoxin were determined using a Cobas Integra 800 automated analyzer (Roche Diagnostics, Rotkreuz, Switzerland). The limit of detection was 0.3 ng/mL, and the measuring range was 0.3–5.0 ng/mL, defined by linearity. For this assay, intermediate precision was 3.9%–9.7% and cross-reactivities with structurally related or potentially coadministered compounds (canrenone, dehydroisoandrosterone, digitoxose, estradiol, estriol, hydrocorosin, 11-hydroxyprogesterone, 17-hydroxyprogesterone, prednisolone, prednisone, spironolactone) were under 0.03%.

EGCG, ECG, EGC, and EC were analyzed from plasma using liquid–liquid extraction method and their concentrations were calculated with a liquid chromatography-tandem mass spectrometry (LC-MS/MS). Briefly, 1 mL of ethyl acetate was added to 100 μL plasma and ascorbic acid-EDTA solution (1 µL of 15% acetonitrile containing 0.3% acetic acid) as internal standard and vortexed for 15 minutes and centrifuged at 3,500 rpm for 20 minutes. After initial collection of 850 μL of the supernatant, the remaining precipitate was repeatedly processed under the same conditions for further extraction, and 600 μL of the supernatant was additionally obtained. The final 1,450 μL was concentrated at 35°C for 60 minutes. After evaporation, the pellet was reconstituted with 100 μL of 15% acetonitrile containing 0.3% acetic acid and centrifuged at 13,000 rpm for 10 minutes, and 5 μL of the supernatant was injected into MS through the Atlantis T3 (4.6×50 mm ×3 μm) C18 (Waters) column were 443.10 → 123.00, 307.20 → 151.00, 291.20 → 139.00, and 199.00 → 127.03, respectively. The confirmation ion from negative mode of EGCG was detected 457.20 → 168.98. Instrumental settings of the ionization were as follows: capillary voltage 2 kV; capillary source temperature at 150°C; desolvation gas temperature at 625°C; cone voltages 25 V for EGCG and ECG, 20 V for EGC and EC, 18 V for ethyl gallate; collision energy 25 V for EGCG, 15 V for EGC and ECG, 12 V for ethyl gallate. Using this LC-MS/MS method, a calibration curve range was generated by 0.1–50 ng/mL for EC and 1–500 ng/mL for EGCG, ECG, and EGC. Lower limit of quantification was determined as the lowest concentration of the calibration curve. The inter- and intrabatch accuracies and precisions of 4 GTCs were 88.85%–110.71% and 0.53%–11.58%, respectively.

**Genotyping**

DNA was isolated from the 200 μL of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA). The concentrations of purified DNAs were quantified by absorbance spectroscopy (260 and 280 nm) between 1.8 and 2.0 using a Nanodrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA). The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582). The PCR reaction mixture consisted of 1 μL of isolated DNA, 5 μL of 2× TaqMan Universal PCR master mix, 0.5 μL of 20× Drug Metabolism Genotyping assay mix, and 3.5 μL of DNase-free water. Genotyping was carried out using the Taqman SNP Genotyping Assays. DNA amplification was performed by real-time PCR using a Light Cycler 96™ (Roche) under the following protocol: initial denaturation at 60°C for 60 seconds and at 95°C for 600 seconds, followed by a 45-cycle amplification step that consists of denaturation at 95°C for 15 seconds and annealing/extension at 60°C for 60 seconds, and final cooling at 60°C for 60 seconds.

**Statistical analysis**

To compare C_{max} and AUC_{last} of digoxin between single administration (Day 1) and concomitant administration with
GTC (Day 15 or Day 29), we performed a mixed-effects analysis in which the subject was a random effect and the treatment was a fixed effect. The analysis was conducted with log-transformed values, and the geometric mean ratios (GMRs) and 90% CIs were obtained by exponentiating the mean difference of the log-transformed values between treatments. The Wilcoxon signed rank test was used to compare $T_{\text{max}}$ of digoxin between single administration (Day 1) and concomitant administration with GTC (Day 15 or Day 29). The Mann–Whitney U-test was used to compare the % changes from Day 1 (digoxin single administration) of $AUC_{\text{last}}$ and $C_{\text{max}}$ between genotypes (wild-type vs variant genotype) in each SNP.

To evaluate the effect of catechin exposure on digoxin transport, correlation between percent change of digoxin $AUC_{\text{last}}$ from Day 1 and $AUC_{\text{last}}$ of catechins was assessed by Pearson correlation coefficient.

SAS® 9.3 (SAS Institute Inc., Cary, NC, USA) was used for statistical analysis. The 2-sided level of statistical significance was set at 0.05.

**Results**

**Study participants**

A total of 16 subjects (11 males and 5 females) were enrolled in this study. One male subject withdrew his consent after Day 15, and so 15 subjects completed the study. The mean age of subjects was 23.1±2.8 years (mean±SD), and weight was 68.8±10.8 kg. The baseline characteristics are presented in Table 1.

**Safety profiling**

Sixteen subjects reported 27 adverse events. Of these, 20 were symptoms related to upper respiratory tract infection such as headache, cough, rhinorrhea, pharyngitis, and sputum. There were 7 cases of adverse events unrelated to upper respiratory tract infection, including single cases of nausea, constipation, and insomnia and 4 cases of headache. Among those adverse events, nausea and constipation were considered possibly related to GTC. All the adverse events were mild in intensity and resolved without any treatment.

**Pharmacokinetics of digoxin**

Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): $AUC_{\text{last}}$ decreased by 31% (GMR [90% CI]: 0.69 [0.62–0.75]) and $C_{\text{max}}$ decreased by 28% (GMR [90% CI]: 0.72 [0.61–0.85]). The concomitant administration of digoxin and GTC at Day 29, following pretreatment with GTC for 13 days, also reduced $AUC_{\text{last}}$ and $C_{\text{max}}$ by 33% and 26%, respectively (GMR [90% CI] of $AUC_{\text{last}}$: 0.67 [0.61–0.74]; GMR [90% CI] of $C_{\text{max}}$: 0.74 [0.63–0.87]) (Figures 2 and 3, Table 2). There was no significant difference in $T_{\text{max}}$ between coadministration of GTC at Day 15 or Day 29 and digoxin alone at Day 1 Table 2.

**Pharmacokinetics of catechins**

The concentration–time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3. All the 4 kinds of catechins showed peak level at 1 hour after administering digoxin, ie, 2 hours after receiving GTC. EGCG accounted for the largest part of total catechins, followed by ECG. The concentrations of EGC and EC were very low compared to EGCG or ECG. There was no correlation between its $AUC_{\text{last}}$ and the reduction of digoxin $AUC_{\text{last}}$ for any of these catechins (Figure 5).

**Effect of SNPs of ABCB1 on GTC–digoxin interaction**

In the comparisons between genotypes in ABCB1, dominant and recessive models were applied depending on the

![Figure 2 Plasma concentration–time profiles of digoxin.](image)

**Notes:** ● Digoxin alone (Day 1); ○ digoxin + GTC (Day 15); ▲ digoxin + GTC + GTC pretreatment (Day 29).

**Abbreviation:** GTC, green tea catechins.

---

**Table 1 Subject baseline characteristics at the start of the study**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>16</td>
</tr>
<tr>
<td>Age (years)</td>
<td>23.1±2.8</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>172.3±7.3</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>68.8±10.8</td>
</tr>
<tr>
<td>Sex</td>
<td>Male:female =11:5</td>
</tr>
</tbody>
</table>

**Note:** Data are presented as mean±SD for continuous variables and as ratios for categorical variables.
distribution of each polymorphism among the subjects: the dominant model (wild-type + heterozygote variant vs homozygote variant) was used for C1236T genotypes and the recessive model (wild-type vs heterozygote + homozygote variant) for G2677A and G2677T genotypes. In case of C3435T, wild-type was compared with heterozygous variant due to the absence of homozygous variant.

To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC$_{\text{last}}$ between genotypes in each SNP. SNPs C3435A and G2677A/T did not show any significant difference in AUC$_{\text{last}}$ between genotypes. The percentage change of Day 15 AUC$_{\text{last}}$ was significantly higher in C1236T homozygous variant type (TT) than in CC and CT genotypes ($P=0.005$). However, there were no significant differences between C1236T genotypes in the percentage changes of AUC$_{\text{last}}$ at Day 29 (Table 4).

**Discussion**

This study investigated the effect of GTC on the pharmacokinetics of digoxin. Compared with digoxin alone, concomitant administration with GTC reduced $C_{\text{max}}$ and AUC$_{\text{last}}$ of digoxin by 28% and 31%, respectively. Pretreatment with GTC for 13 days

**Table 2** Pharmacokinetic parameters of digoxin according to treatment

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Digoxin alone (Day 1) (N=16)</th>
<th>Digoxin + GTC (Day 15) (N=16)</th>
<th>Digoxin + GTC + GTC pretreatment (Day 29) (N=15)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$T_{\text{max}}$ (h)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>1.15</td>
<td>1.21</td>
<td>1.13</td>
</tr>
<tr>
<td>Min, max</td>
<td>1.0, 2.0</td>
<td>1.0, 4.0</td>
<td>1.0, 2.0</td>
</tr>
<tr>
<td>P-value*</td>
<td>–</td>
<td>0.478</td>
<td>0.603</td>
</tr>
<tr>
<td>$C_{\text{max}}$ (ng/mL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>2.47</td>
<td>1.75</td>
<td>1.76</td>
</tr>
<tr>
<td>SD</td>
<td>0.99</td>
<td>0.61</td>
<td>0.67</td>
</tr>
<tr>
<td>GMR (90% CI)</td>
<td>–</td>
<td>0.72 (0.61–0.85)</td>
<td>0.74 (0.63–0.87)</td>
</tr>
<tr>
<td>AUC$_{\text{last}}$ (ng h/mL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>8.20</td>
<td>5.51</td>
<td>5.44</td>
</tr>
<tr>
<td>SD</td>
<td>2.45</td>
<td>1.22</td>
<td>1.74</td>
</tr>
<tr>
<td>GMR (90% CI)</td>
<td>–</td>
<td>0.69 (0.62–0.75)</td>
<td>0.67 (0.61–0.74)</td>
</tr>
</tbody>
</table>

Note: *Comparisons between Day 1 and Day 15 or between Day 1 and Day 29.

Abbreviations: GTC, green tea catechin; $T_{\text{max}}$, time to $C_{\text{max}}$; $C_{\text{max}}$, peak plasma concentration; AUC$_{\text{last}}$, area under the concentration–time curve from time 0 to the last measurable time; GMR, geometric mean ratio to Day 1 value; CI, confidence interval.
did not alter the effect of concomitant GTC administration on the pharmacokinetics of digoxin: $C_{\text{max}}$ and $\text{AUC}_{\text{last}}$ of digoxin decreased by 26% and 33%, respectively, with concomitant GTC and digoxin administration following GTC pretreatment.

Apparently, these findings are not consistent with the known role of p-gp in drug absorption and elimination. P-gp is abundantly expressed on the luminal membrane of enterocytes, hepatocytes facing biliary canaliculi, and renal proximal tubular epithelial cells, so that it interrupts the absorption of substrate drugs and facilitates their excretion. Given the in vitro study reporting the inhibitory effect of GTC on the activity of p-gp, we hypothesized that the systemic exposure of digoxin would increase after concomitant administration of GTC. Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study. Although previous studies on the interaction between p-gp inhibitors and digoxin have consistently reported an increase in the systemic exposure of digoxin, a similar observation was previously reported as an abstract, in which the $\text{AUC (0–4 hours)}$ of digoxin measured in 8 healthy human subjects decreased by 7% (statistically insignificant) and 2 of them exhibited a 40% decrease in $\text{AUC (0–4 hours)}$ and $C_{\text{max}}$.

We believe that the reduction in systemic exposure to digoxin following concomitant GTC use can be explained by one of the following: 1) enhanced p-gp activity by EC and 2) inhibition of digoxin uptake transporters by GTC. Distinct from other catechins, EC has been reported to enhance the efflux function of p-gp possibly by binding to an allosteric site of p-gp that increases its activity.

Table 3 Pharmacokinetic parameters of catechins

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Digoxin + GTC (Day 15) (N=16)</th>
<th>Digoxin + GTC + GTC pretreatment (Day 29) (N=15)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EC</td>
<td>EGC</td>
</tr>
<tr>
<td>$C_{\text{max}}$ (ng/mL) Mean</td>
<td>1.79</td>
<td>14.58</td>
</tr>
<tr>
<td>SD</td>
<td>1.04</td>
<td>8.55</td>
</tr>
<tr>
<td>$\text{AUC}_{\text{last}}$ (ng⋅h/mL) Mean</td>
<td>5.36</td>
<td>44.71</td>
</tr>
<tr>
<td>SD</td>
<td>2.69</td>
<td>25.73</td>
</tr>
</tbody>
</table>

Abbreviations: GTC, green tea catechin; EC, (-)-epicatechin; EGC, (-)-epigallocatechin; ECG, (-)-epicatechin gallate; EGCG, (-)-epigallocatechin gallate; $C_{\text{max}}$, peak plasma concentration; $\text{AUC}_{\text{last}}$, area under the concentration–time curve from time 0 to the last measurable time.
Effect of GTC on the pharmacokinetics of digoxin in humans

Figure 5 Relationship between the catechin AUC_{last} and % changes of digoxin AUC_{last} (A) from digoxin alone (Day 1) to digoxin + GTC (Day 15) and (B) from digoxin alone (Day 1) to digoxin + GTC + GTC pretreatment (Day 29).

Abbreviations: AUC_{last}, area under the concentration–time curve from time 0 to the last measurable time; EC, (−)-epicatechin; EGC, (−)-epigallocatechin; ECG, (−)-epicatechin gallate; EGCG, (−)-epigallocatechin gallate; GTC, green tea catechin.
other membrane transporters reportedly involved in the transport of digoxin. Although digoxin was recommended as one of the most suitable substrates for p-gp studies, most p-gp inducers or inhibitors cause only modest changes in the pharmacokinetics of digoxin (20%–30% changes in digoxin AUC or $C_{max}$). Therefore, digoxin absorption may not be highly dependent on p-gp. In addition, multiple studies reported that digoxin is likely to be a substrate of uptake transporters.

Taub et al suggested that digoxin could be a substrate of a sodium-dependent uptake transporter, by demonstrating the significant increase of digoxin uptake in cells incubated with sodium-fortified media. Kobayashi et al reported that ribosomal protein L in Xenopus laevis oocyte mediated the uptake of digoxin. Lumen et al demonstrated by data simulation that digoxin transport into MDCK-MDR1-NKI cells involved an uptake transporter as well as p-gp. Although specific transporters were not identified and involvement of uptake transporters in digoxin pharmacokinetics has not yet been evaluated in vivo, the existence of uptake transporter found in these studies agrees with our findings.

In this study, a 630 mg capsule of green tea extract containing 300 mg of catechins was used as the source of GTC. According to a previous report which investigated the ingredients of various green tea products and green tea supplements, the total amount of catechins brewed in 100 mL of water or contained in a capsule was highly variable, ranging from 52.7 to 584.8 mg. Also, green tea products available in the market were found to have differing compositions of catechins. While it would be reasonable to assume that a higher dose of catechins would elicit a stronger interaction with digoxin, our study did not establish a dose–response relationship regarding GTC–digoxin interaction since only one dose of GTC was used. Given the variable amount of catechins contained in green tea products and the differing chemical compositions of catechins, our finding might not generalize to every case of concomitant administration of digoxin and a green tea product. In particular, systemic exposure of digoxin may not be reduced at all if digoxin is taken with a green tea product containing a very small amount of catechins.

There are some limitations in this study. This study was designed to collect blood sample up to 8 hours post-dose. Since the terminal elimination half-life of digoxin is 26–45 hours, blood sampling for 8 hours is not sufficient for evaluating pharmacokinetic characteristics of the elimination phase. Despite the lack of data from the elimination phase, collection of more blood samples beyond 8 hours after administration of digoxin is unlikely to have made a difference for the following reasons. First, it is highly unlikely that digoxin and GTC have significant interaction in the intestinal lumen at 8 hours after administration because most of the digoxin and GTC will have been absorbed by that time. Second, the concentrations of catechins reported in previous studies on the inhibitory effect of catechins on organic anion transporters were much higher than the plasma concentrations of EGCG found in our subjects. Roth et al reported that the $IC_{50}$ concentrations of EGCG and ECG were 7.8–101 µM (3.573.492–46,272.14 ng/mL) and 10.2–58.6 µM (4,512.174–25,922.88 ng/mL), respectively, and Knop et al

---

**Table 4** Pharmacokinetic parameters of digoxin in each treatment according to genotype and treatment

<table>
<thead>
<tr>
<th>Genotype</th>
<th>N</th>
<th><strong>AUC_{area}</strong> (ng·h/mL)</th>
<th><strong>AUC_{area}</strong> (ng·h/mL)</th>
<th><strong>AUC_{area}</strong> (ng·h/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Digoxin alone (Day 1)</td>
<td>Digoxin + GTC (Day 15)</td>
<td>Digoxin + GTC + GTC pretreatment (Day 29)</td>
</tr>
<tr>
<td></td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
<td></td>
</tr>
<tr>
<td>C3435T (rs1045642)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC (wild-type)</td>
<td>7</td>
<td>7.78±1.88</td>
<td>5.12±0.93</td>
<td>5.12±1.95</td>
</tr>
<tr>
<td>CT</td>
<td>9</td>
<td>9.00±2.63</td>
<td>5.81±1.39</td>
<td>5.73±1.61</td>
</tr>
<tr>
<td>P-value</td>
<td></td>
<td></td>
<td>0.223</td>
<td>0.728</td>
</tr>
<tr>
<td>C1236T (rs1128503)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC (wild-type)</td>
<td>2</td>
<td>7.33±0.93</td>
<td>5.10±0.52</td>
<td>4.24±0.01</td>
</tr>
<tr>
<td>CT</td>
<td>6</td>
<td>6.63±2.50</td>
<td>5.40±1.38</td>
<td>5.04±1.85</td>
</tr>
<tr>
<td>TT</td>
<td>8</td>
<td>9.59±1.92</td>
<td>5.69±1.31</td>
<td>6.14±1.73</td>
</tr>
<tr>
<td>P-value</td>
<td></td>
<td></td>
<td>0.005</td>
<td>0.247</td>
</tr>
<tr>
<td>G2677A/T (rs2032582)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GG (wild-type)</td>
<td>6</td>
<td>7.54±1.78</td>
<td>4.99±0.95</td>
<td>5.36±2.02</td>
</tr>
<tr>
<td>GT</td>
<td>7</td>
<td>9.27±2.81</td>
<td>6.07±1.36</td>
<td>6.05±1.43</td>
</tr>
<tr>
<td>GA</td>
<td>1</td>
<td>5.03</td>
<td>5.89</td>
<td>3.69</td>
</tr>
<tr>
<td>TA</td>
<td>2</td>
<td>8.03±2.40</td>
<td>4.93±1.47</td>
<td>3.46</td>
</tr>
<tr>
<td>P-value</td>
<td></td>
<td></td>
<td>0.787</td>
<td>0.406</td>
</tr>
</tbody>
</table>

**Note:** Comparisons of the % changes from Day 1 between genotypes (wild-type vs variant genotype).

**Abbreviations:** AUC_{area}, area under the concentration–time curve from time 0 to the last measurable time; GTC, green tea catechin.
used ECGC at 1–100 μM (458.14–45,814 ng/mL) to study the effect of EGCGR on various transporters. The plasma concentrations of EGCGR reported at 8 hours of administration in our study subjects ranged from 4.24 to 119.68 ng/mL, lower than those in previous studies by several orders of magnitude. We believe that plasma concentrations of EGCGR beyond 8 hours of administration are too low to exhibit any biologically relevant interaction between catechins and digoxin.

**Conclusion**

We observed that concomitant administration of GTC significantly reduces the systemic exposure of digoxin, with or without pretreatment with GTC. Our findings suggest that caution might be needed in case of prescribing digoxin to a patient taking green tea or green tea supplement on a regular basis. This study did not investigate the mechanism for the finding. Further studies are needed on the role of each green tea ingredient or other digoxin transporters to clarify the green tea–digoxin interaction.

**Acknowledgment**

This work was supported by the National Research Foundation of Korea (NRF) grant (No NRF-2017R1D1A1B03035766). Dr Kim was supported by a training program grant from the Korea Healthcare Technology R&D Project, Ministry for Health & Welfare, Republic of Korea (HI14C2339).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


---

**Published work in this journal**

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.